9 Stocks To Buy For Long Term: Motilal Oswal, Sharekhan bullish on ICICI Prudential Life Insurance, Punjab National Bank, Trent; up to 42% upside

Sharekhan has maintained a Buy rating on PNB, with the stock trading at Rs 109.36 and a target price of Rs 145, implying an upside of around 32.6 per cent. Improving asset quality, stable margins and healthy credit growth support the investment case.

Sharekhan remains bullish on ICICI Prudential Life Insurance, with the stock trading at Rs 513.85 and a target price of Rs 715, indicating an upside of around 39.1 per cent. Improving product mix and strong traction in protection business are likely to support earnings growth.

Sharekhan has maintained a Buy rating on V2 Retail, with the stock trading at Rs 198.65 and a target price of Rs 281, implying an upside of around 41.5 per cent. The brokerage expects strong growth driven by aggressive store expansion and rising demand in tier-2 and tier-3 markets.

Motilal Oswal has maintained a Buy rating on Trent, with the stock trading at Rs 4,144.60 and a target price of Rs 5,250, implying an upside of around 26.6 per cent. Continued store expansion, improving margins and strong retail traction remain key drivers.

Motilal Oswal remains positive on Persistent Systems, with the stock trading at Rs 4,800.00 and a target price of Rs 6,200, indicating an upside of around 29.2 per cent. Strong deal pipeline, digital demand and execution capabilities are expected to drive growth.

Motilal Oswal remains bullish on CEAT, with the stock trading at Rs 3,445.20 and a target price of Rs 4,228, indicating an upside of around 22.7 per cent. Demand recovery and pricing actions are expected to support margin stability.

Motilal Oswal has maintained a Buy rating on Piramal Pharma, with the stock trading at Rs 161.87 and a target price of Rs 190, implying an upside of around 17.4 per cent. Recovery in CDMO and improving profitability outlook support growth.

Motilal Oswal remains positive on Federal Bank, with the stock trading at Rs 286.95 and a target price of Rs 325, indicating an upside of around 13.3 per cent. NIM expansion, strong CASA growth and improving asset quality support earnings visibility.

Sharekhan has maintained a Buy rating on Zydus Wellness, with the stock trading at Rs 508.55 and a target price of Rs 552, implying an upside of around 8.5 per cent. Stable demand and strong brand portfolio support steady growth.

The views/suggestions/recommendations expressed in this article are solely those of investment experts. The platform does not advise investors to buy or sell stocks. Please consult your financial adviser before making investment decisions.